Audited Financial Results along with Auditors Report for the half year and financial Year ended on 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 3.2 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mahamaya Lifesciences reported strong full-year results for FY26 with revenue from operations growing 24.5% to Rs 32,887.30 lakhs from Rs 26,414.86 lakhs in FY25. Standalone profit after tax increased 30.4% to Rs 1,672.08 lakhs from Rs 1,282.07 lakhs. EPS improved to Rs 8.43 from Rs 7.55. This is the company's first set of results since listing on BSE SME in November 2025 through an IPO raising Rs 64.28 crore. The auditors issued an unmodified (clean) opinion. However, operating cash flow remained deeply negative at Rs 2,957.73 lakhs due to significant buildup in inventories (up Rs 4,084.50 lakhs) and trade receivables (up Rs 2,229.70 lakhs). IPO proceeds of Rs 3,279.36 lakhs remain unutilized and parked in fixed deposits.
The company demonstrated robust top-line and bottom-line growth as a newly listed entity, but the negative operating cash flow and rising working capital requirements raise concerns about cash conversion quality despite healthy profitability.